Akesobio

Focus: Akesobio is a China-based biotechnology company specializing in antibody therapies for oncology, with commercial-stage presence anchored by VONJO (pacritinib) for myelofibrosis indications.

Oncology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Akesobio

AI assessmentNot Hiring

No open roles listed right now. Follow Akesobio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

1 in 5yr

VONJO

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

VONJO

Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis

$93M Part D

Peak

Help build intelligence for Akesobio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a commercially approved oncology franchise (VONJO generating $93M in Part D spending) with established market presence
Diverse pipeline of 9 programs spanning Phase 1-3 with focus on high-value oncology and immunology indications including Phase 3 cadonilimab
Mid-cap scale offers hands-on impact in R&D and commercial operations without mega-pharma bureaucracy

Watch Out For

Extreme revenue concentration risk: 100% dependency on single asset (VONJO) creates vulnerability to competitive or regulatory headwinds
Only 1 active job posting signals minimal near-term hiring; limited pipeline maturity (1 Phase 3, 10 Phase 2, 9 Phase 1 programs) suggests long runway before next major catalysts

Generated by Claude from Akesobio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Only approved commercial product; tyrosine kinase inhibitor with ~6-year exclusivity window before patent expiration.

Pipeline & Clinical Trials

AK105

Advanced Cancer

Phase 1

Clinical Trials (1)

NCT03352531Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors

Phase 1

AK112

Neoplasms Malignant

Phase 1

Clinical Trials (3)

NCT06491472Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

Phase 2

NCT06936644A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation

AK111

Psoriasis

Phase 1

Clinical Trials (1)

NCT03622021A Study of AK111 in Healthy Subjects

Phase 1

AK119

Coronavirus Disease 2019 (COVID-19)

Phase 1

Clinical Trials (1)

NCT04516564A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects

Phase 1

AK117

Neoplasms Malignant

Phase 1

AK104

Advanced Cancer

Phase 2

Clinical Trials (4)

NCT04380805A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

Phase 2

NCT05021120A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

ivonescimab

Advanced Solid Tumors

Phase 2

Clinical Trials (2)

NCT06959550Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Phase 2

NCT07412262A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression

AK120

Atopic Dermatitis

Phase 2

Clinical Trials (2)

NCT05048056Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Phase 2

NCT04256174A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

ligufalimab

Advanced Hepatocellular Carcinoma

Phase 2

Clinical Trials (1)

NCT06789848Ligufalimab and Cadonilimab in Advanced Liver Cancers

Phase 2

cadonilimab

Pleural Mesothelioma

Phase 3

Clinical Trials (3)

NCT07400536A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT

Phase 3

NCT06187961HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2012

Portfolio: 1 approved product, 18 clinical trials

Top TAs: Oncology, Immunology, Hematology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Peak1 (100%)

1 total products

Therapeutic Area Focus

Oncology

1 marketed14 pipeline

Immunology

3 pipeline

Hematology

1 marketed

Infectious Diseases

1 pipeline

Marketed

Pipeline

NCT04047290A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Phase 1

NCT04349969A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104

Phase 1

NCT06416930Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

Phase 2

Akesobio

About Akesobio

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Key Products by Revenue

Pipeline & Clinical Trials

Open Jobs (0)